Rare disease drugmaker · based in Lexington, United States · founded 2015 · ticker KROS · kerostx.com
Keros Therapeutics works on Duchenne Muscular Dystrophy and Myelofibrosis, 2 of the rare diseases we track. It has 1 active clinical trial, and it is looking for volunteers now.
Keros Therapeutics is a clinical-stage biopharmaceutical company developing therapies for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-beta) family of proteins. The company's lead product candidate, rinvatercept (KER-065), is in Phase 2 for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Keros Therapeutics pipeline
Each row lists the diseases Keros Therapeutics is studying at that stage, from the ones closest to approval down to the earliest work.
Phase 2
Mid-size studies that check whether a drug works and at what dose.
These are Keros Therapeutics trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.
1 trial looking for volunteers now
Looking for volunteersPhase 2Recently updatedNCT07704099
Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background therapy.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Keros Therapeutics. Unsubscribe anytime.
You'll get, for Duchenne Muscular Dystrophy:
Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
Its most advanced product candidate, elritercept (KER-050), is in development for cytopenias including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis, and is partnered with Takeda. Keros stopped all development of cibotercept (KER-012) in pulmonary arterial hypertension on May 29, 2025, after fluid around the heart (pericardial effusions) led it to halt dosing in the Phase 2 TROPOS trial and its review of all safety and efficacy data.
Where Keros Therapeutics trials take place
The trials above run at 4 study sites in 2 countries. Tap a country to see its states, cities and hospitals.
Georgia
2▼
New Zealand
2▼
Rare diseases Keros Therapeutics works on
Each disease page lists every open trial, not only Keros Therapeutics's, plus approved treatments.
Myelofibrosis is a myeloproliferativeneoplasm in which bone marrow develops scarring (fibrosis), leading to anemia, enlarged spleen, and abnormal blood cell counts.
How common: Approximately 0.5-1.5 cases per 100,000 people; median age of diagnosis is 65 years
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Keros Therapeutics's own site is kerostx.com, and our help paying for treatment page lists drugmaker programs and charity funds.
1 shared disease, including Duchenne Muscular Dystrophy
Questions about Keros Therapeutics
Keros Therapeutics is a clinical-stage biopharmaceutical company developing therapies for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-beta) family of proteins. The company's lead product candidate, rinvatercept (KER-065), is in Phase 2 for Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its most advanced product candidate, elritercept (KER-050), is in development for cytopenias including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis, and is partnered with Takeda. Keros stopped all development of cibotercept (KER-012) in pulmonary arterial hypertension on May 29, 2025, after fluid around the heart (pericardial effusions) led it to halt dosing in the Phase 2 TROPOS trial and its review of all safety and efficacy data.
Keros Therapeutics has active programs across 2 rare diseases: Duchenne Muscular Dystrophy, Myelofibrosis. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.
Yes. Keros Therapeutics is a rare disease specialist headquartered in Lexington, United States, founded in 2015. The company focuses primarily on developing treatments for rare and orphan diseases, with programs targeting Duchenne Muscular Dystrophy, Myelofibrosis.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Keros Therapeutics, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
None that we track as of November 2026. No Keros Therapeutics label in the FDA's openFDA database matches a rare disease on Trial Friend, which usually means the company has no approved product yet or its approved drugs are for common conditions.
In development: the trials list on this page shows what Keros Therapeutics is recruiting for now, and the FDA calendar lists any application once a decision date is public.
Keros Therapeutics was founded in 2015 and is headquartered in Lexington, United States. The company has been active for 11 years. It trades publicly under the ticker symbol KROS. As a rare disease specialist, the company dedicates its resources to developing therapies for patients with rare and orphan conditions.